The role of government fiscal and tax incentives in green technology innovation and enterprise development: implications for human health and hygiene by Yinghong Shi, Jing Ge

Get full text

Natural killer cell-based cancer immunotherapy: from basics to clinical trials by Yinghong Shi, Donglin Hao, Hui Qian, Zhimin Tao

Get full text

Duration of hepatic portal occlusion is a valuable predictor for postoperative nausea and vomiting in patients underwent liver resection for liver cancer by Xiao Chen, Wen Juan Zhao, Jingxian Yu, Haiying Zhou, Yinghong Shi, Jian Gao, Yuxia Zhang

Get full text

Plasma miRNA testing in the differential diagnosis of very early-stage hepatocellular carcinoma: a multicenter real-world study by Jie HU, Ying XU, Ao HUANG, Lei YU, Zheng WANG, Xiaoying WANG, Xinrong YANG, Zhenbin DING, Qinghai YE, Yinghong SHI, Shuangjian QIU, Huichuan SUN, Qiang GAO, Jia FAN, Jian ZHOU

Get full text

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma by Yan Lu, Shuang Zhou, Han Wang, Fangming Liu, Weiren Liu, Chunhui Yang, Mengxin Tian, Guangshuai Jia, Bijun Zhu, Mingxiang Feng, Tiankui Qiao, Xinxin Wang, Wei Cao, Xiangdong Wang, Yinghong Shi, Duojiao Wu

Get full text

Landscape analysis of m5C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma by Xuhui Zhao, Shengwei Mao, Yuan Fang, Jiafeng Chen, Lifu Bi, Jie Li, Jinglei Wu, Jun Gao, Shiguang Yang, Jialu Fu, Xiaoling Wu, Guiqi Zhu, Zheng Tang, Yinghong Shi, Jian Zhou, Jia Fan, Xingxing Zhang, Jinling Jiang, Weiren Liu

Get full text

Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma by Tianhao Chu, Guiqi Zhu, Zheng Tang, Weifeng Qu, Rui Yang, Haiting Pan, Yi Wang, Ruilin Tian, Leilei Chen, Zhiqi Guan, Yichao Bu, Qianfu Zhao, Jiafeng Chen, Shengwei Mao, Yuan Fang, Jun Gao, Xiaoling Wu, Jian Zhou, Weiren Liu, Dan Ye, Jia Fan, Yinghong Shi

Get full text

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study by Guoming Shi, Xiaoyong Huang, Liang Ma, Hui Li, Jianhong Zhong, Junye Wang, Qiang Gao, Xiaojun Guo, Shuangjian Qiu, Huichuan Sun, Yinghong Shi, Xiaowu Huang, Xiaoying Wang, Yong Yi, Xiaodong Zhu, Cheng Huang, Zhenbin Ding, Yi Chen, Yifeng He, Yinghao Shen, Qiman Sun, Jian Zhou, Jia Fan

Get full text